Accelerated Pharma (Accelerated Pharma) EV-to-EBIT : 0.00 (As of May. 17, 2024)

View and export this data going back to 2016. Start your Free Trial

What is Accelerated Pharma EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Accelerated Pharma's Enterprise Value is $0.00 Mil. Accelerated Pharma's EBIT for the trailing twelve months (TTM) ended in Mar. 2017 was $-1.98 Mil. Therefore, Accelerated Pharma's EV-to-EBIT for today is 0.00.

The historical rank and industry rank for Accelerated Pharma's EV-to-EBIT or its related term are showing as below:

ACCP's EV-to-EBIT is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 17.9
* Ranked among companies with meaningful EV-to-EBIT only.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Accelerated Pharma's Enterprise Value for the quarter that ended in Mar. 2017 was $0.00 Mil. Accelerated Pharma's EBIT for the trailing twelve months (TTM) ended in Mar. 2017 was $-1.98 Mil. Accelerated Pharma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2017 was %.

Accelerated Pharma EV-to-EBIT Historical Data

The historical data trend for Accelerated Pharma's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Accelerated Pharma EV-to-EBIT Chart

Accelerated Pharma Annual Data

Trend

Dec14

Dec15

Dec16

EV-to-EBIT

Accelerated Pharma Quarterly Data
	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17
EV-to-EBIT	Get a 7-Day Free Trial			-	-	-	-	-

Competitive Comparison of Accelerated Pharma's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Accelerated Pharma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Accelerated Pharma's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Accelerated Pharma's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Accelerated Pharma's EV-to-EBIT falls into.

Accelerated Pharma EV-to-EBIT Calculation

Accelerated Pharma's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	0.000	/	-1.976
	=	0.00

Accelerated Pharma's current Enterprise Value is $0.00 Mil.
Accelerated Pharma's EBIT for the trailing twelve months (TTM) ended in Mar. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.98 Mil.

Accelerated Pharma (NAS:ACCP) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Accelerated Pharma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2017 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2017 )	=	EBIT	/	Enterprise Value (Q: Mar. 2017 )
	=	-1.976	/	0
	=	%

Accelerated Pharma's Enterprise Value for the quarter that ended in Mar. 2017 was $0.00 Mil.
Accelerated Pharma's EBIT for the trailing twelve months (TTM) ended in Mar. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.98 Mil.

Accelerated Pharma EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Accelerated Pharma's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Accelerated Pharma (Accelerated Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Accelerated Pharma Inc (NAS:ACCP) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Accelerated Pharma Inc, is a Delaware corporation organized on May 12, 2014. It is a biopharmaceutical company focused on utilizing its genomic technology to enhance the development and commercialization of pharmaceutical products. Its lead product candidate is Picoplatin, a new generation platinum-based cancer therapy that has the potential for use in different formulations, as a single agent or in combination with other anti-cancer agents, to treat multiple cancer indications.

Accelerated Pharma (Accelerated Pharma) Headlines

No Headlines